Equities research analysts at Oppenheimer assumed coverage on shares of Axsome Therapeutics (NASDAQ:...
Oppenheimer began coverage on Axsome Therapeutics in a report on Tuesday. They issued an "outperform...
In a report dated May 30, Morgan Stanley analyst Vikram Purohit reaffirmed his Buy rating on Axsome ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is capturing the attention of investors with its promising ...